Land: Singapore
Språk: engelska
Källa: HSA (Health Sciences Authority)
CLINDAMYCIN PHOSPHATE EQV CLINDAMYCIN
PFIZER PRIVATE LIMITED
J01FF01
150 mg/ml
INJECTION
CLINDAMYCIN PHOSPHATE EQV CLINDAMYCIN 150 mg/ml
INTRAVENOUS, INTRAMUSCULAR
Prescription Only
PFIZER MANUFACTURING BELGIUM NV
ACTIVE
1988-05-25
1. NAME OF THE MEDICINAL PRODUCT DALACIN. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Ingredient: clindamycin hydrochloride or palmitate hydrochloride or phosphate. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin. Clindamycin hydrochloride is the hydrated hydrochloride salt of clindamycin. Each capsule contains clindamycin hydrochloride equivalent to 150 mg or 300 mg of clindamycin. Clindamycin palmitate hydrochloride is a water soluble salt of the ester of clindamycin and palmitic acid. Clindamycin pediatric flavored granules contain clindamycin palmitate hydrochloride for reconstitution. Each 5 mL contains the equivalent of 75 mg clindamycin. Clindamycin phosphate is a water-soluble ester of clindamycin and phosphoric acid. Each mL contains the equivalent of 150 mg clindamycin, 0.5 mg disodium edetate and 9.45 mg benzyl alcohol added as preservative in each mL. 3. PHARMACEUTICAL FORM Capsules, Granules for oral solution, Solution for injection. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS Clindamycin has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram positive aerobic bacteria such as streptococci, staphylococci and pneumococci. 1. Upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever. 2. Lower respiratory infections including bronchitis, pneumonia, empyema and lung abscess. 3. Skin and soft tissue infections including acne, furuncles, cellulitis, impetigo, abscesses and wound infections, specific skin and soft tissue infections caused by susceptible organisms like erysipelas and paranychia (panaritium). 4. Bone Läs hela dokumentet
1. NAME OF THE MEDICINAL PRODUCT DALACIN™ 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Ingredient: clindamycin hydrochloride or clindamycin phosphate. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)- hydroxyl group of the parent compound lincomycin. Clindamycin hydrochloride is the hydrated hydrochloride salt of clindamycin. Each capsule contains clindamycin hydrochloride equivalent to 150 mg or 300 mg of clindamycin. Clindamycin phosphate is a water-soluble ester of clindamycin and phosphoric acid. Each mL contains the equivalent of 150 mg clindamycin, 0.5 mg disodium edetate and 9.45 mg benzyl alcohol added as preservative in each mL. 3. PHARMACEUTICAL FORM Capsules, Solution for injection. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS Clindamycin has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram-positive aerobic bacteria such as streptococci, staphylococci and pneumococci. 1. Upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever. 2. Lower respiratory infections including bronchitis, pneumonia, empyema and lung abscess. 3. Skin and soft tissue infections including acne, furuncles, cellulitis, impetigo, abscesses and wound infections, specific skin and soft tissue infections caused by susceptible organisms like erysipelas and paronychia (panaritium). 4. Bone and joint infections including osteomyelitis and septic arthritis. 5. Gynecological infections including endometritis, cellulitis, vaginal cuff infection, tubo- ovarian abscess, salpingitis, and pelvic inflammatory disease when given in conjunction with an antibiotic of appropriate gram-negative spectrum. 6. Intra-abdominal infections including peritonitis and abdominal abscess when given in conjunction with an antibiotic of appropriate gram-negative spectrum. 7. Septicemia and endocarditis. The effectiveness of clindamycin in the treatment of se Läs hela dokumentet